Neurology News and Research

Latest Neurology News and Research

Rituxan drug effective for treating ANCA-associated vasculitis

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.

19 Oct 2009

Recently approved Gleevec drug for cancer treatment

Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news will be presented at the annual meeting of the American College of Rheumatology on October 18 in Philadelphia.

19 Oct 2009

Study reveals the cost effectiveness of Rheos blood pressure lowering device

A study conducted by the University of Rochester Medical Center demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may be a cost effective treatment. The implantable device, called Rheos, is in advanced stages of testing for individuals with drug resistant hypertension.

19 Oct 2009

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Jazz Pharmaceuticals, Inc. announced that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress (US Psych Congress) in Las Vegas, Nevada.

15 Oct 2009

Study shows elevated levels of antioxidant urate can slow the progression of Parkinson's disease

By examining data from a 20-year-old clinical trial, a research team based at the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND) and Harvard School of Public Health (HSPH), has found evidence supporting the findings of their 2008 study - that elevated levels of the antioxidant urate may slow the progression of Parkinson's disease.

14 Oct 2009

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Individuals with Parkinson's disease who have higher levels of a metabolite called urate in their blood and in cerebrospinal fluid (CSF) have a slower rate of disease progression, according to a study funded by the National Institutes of Health.

14 Oct 2009

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

The National Institutes of Health (NIH) has awarded a "Grand Opportunity" grant of $3.7 million to a consortium formed with the Gladstone Institute of Neurological Disease (GIND) and the Taube-Koret Center for Huntington's Disease Research to use stem cell technology to better understand Huntington's disease (HD) and to develop potential therapies.

14 Oct 2009

Talecris Biotherapeutics Holdings to raise $550 million through private placement

Talecris Biotherapeutics Holdings Corp. today announced that it has commenced an offering through a private placement of $550 million aggregate principal amount of senior notes due 2016 (the “Notes”). Talecris intends to use the proceeds from the offering to repay its First and Second Lien Term Loans, repay a portion of borrowings under its Revolving Credit Facility, and to pay related fees and expenses.

13 Oct 2009

New mouse models resembles human ALS; may provide important tool for screening new drugs

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

New sports division established to address athletes' neurological problems

On the football field, the hockey rink or wrestling mat, an athletes' head can take a beating -- and a University of Michigan neurologist is leading the charge to help doctors who treat the brain better understand those sports injuries.

13 Oct 2009

The third annual AdvaMed 2009: The MedTech Conference commences today

Leaders of the medical technology industry convene today through the 14th at the Walter E. Washington Convention Center for the third annual AdvaMed 2009: The MedTech Conference.

13 Oct 2009

Thomson Reuters's NeoFax deployed at the University of Kansas Hospital for electronic neonatal drug dosing

The University of Kansas Hospital has deployed NeoFax(®) from Thomson Reuters to provide physicians, nurses, and pharmacy staff in its neonatal intensive care unit with electronic drug dosing, interaction checking, and reference information.

13 Oct 2009

Guidelines for treating amyotrophic lateral sclerosis identified

New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Oct 2009

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl®1 (triptorelin embonate2 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.

13 Oct 2009

New guidelines for treating amyotropic lateral sclerosis

Dr. John England, Professor and Chairman of Neurology at LSU Health Sciences Center New Orleans, analyzed research findings and was responsible for the quality and accuracy of evidence analysis and the conclusions of the studies resulting in new guidelines for treating Lou Gehrig's disease, or amyotropic lateral sclerosis (ALS).

13 Oct 2009

Cognitive abilites other than memory may decline prior to clinical diagnosis in patients with Alzheimer's disease

Cognitive abilities other than memory, including visuospatial skills needed to perceive relationships between objects, may decline years prior to a clinical diagnosis in patients with Alzheimer's disease, according to a report in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

13 Oct 2009

CNF launches new educational website centered on infantile spasms

The Child Neurology Foundation (CNF) today announced the launch of a new educational website centered on infantile spasms (IS). The website, www.infantilespasmsinfo.org, is an educational resource developed by the CNF as one of the key components of Infantile Spasms Awareness Week.

12 Oct 2009

Sage Practice Analytics system from Sage Software Healthcare

Physicians in ambulatory practice and their administrative leaders can have unsurpassed visibility into their business and clinical data with the Sage Practice Analytics v 5.5 business and clinical intelligence system, released today by Sage.

12 Oct 2009

Neurology News and Research

Latest Neurology News and Research

Rituxan drug effective for treating ANCA-associated vasculitis

Recently approved Gleevec drug for cancer treatment

Study reveals the cost effectiveness of Rheos blood pressure lowering device

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Study shows elevated levels of antioxidant urate can slow the progression of Parkinson's disease

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

Talecris Biotherapeutics Holdings to raise $550 million through private placement

New mouse models resembles human ALS; may provide important tool for screening new drugs

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

New sports division established to address athletes' neurological problems

The third annual AdvaMed 2009: The MedTech Conference commences today

Thomson Reuters's NeoFax deployed at the University of Kansas Hospital for electronic neonatal drug dosing

Guidelines for treating amyotrophic lateral sclerosis identified

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

New guidelines for treating amyotropic lateral sclerosis

Cognitive abilites other than memory may decline prior to clinical diagnosis in patients with Alzheimer's disease

CNF launches new educational website centered on infantile spasms

Sage Practice Analytics system from Sage Software Healthcare

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Neurology News and Research

Latest Neurology News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in